Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

Redas Trepiakas, Annika Berntsen, Sine Reker Hadrup, Jon Bjørn, Poul F. Geertsen, Per Thor Straten, Mads Hald Andersen, Anders Elm Pedersen, Amir Soleimani, Torben Lorentzen, Julia S. Johansen, Inge Marie Svane

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Dendritic cells are regarded as the most effective antigen presenting cells and coordinators of the immune response and therefore suitable as vaccine basis. Here we present results from a clinical study in which patients with malignant melanoma (MM) with verified progressive disease received vaccination with autologous monocyte-derived mature dendritic cells (DC) pulsed with p53, survivin and telomerase-derived peptides (HLA-A2+ patients) or with autologous/allogeneic tumor lysate (HLA-A2(-) patients) in combination with low-dose interleukin (IL)-2 and interferon (IFN)-alpha2b.
Original languageEnglish
JournalCytotherapy
Volume12
Issue number6
Pages (from-to)721-734
Number of pages14
ISSN1465-3249
DOIs
Publication statusPublished - 2010
Externally publishedYes

Fingerprint Dive into the research topics of 'Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial'. Together they form a unique fingerprint.

Cite this